We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+15.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$219M
AUM Growth
+$95.8M
(+78%)
Cap. Flow
+$80.7M
Cap. Flow
% of AUM
36.91%
Top 10 Holdings %
Top 10 Hldgs %
33.7%
Holding
163
New
55
Increased
48
Reduced
23
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco DB Commodity Index Tracking Fund
DBC
|
+$32.3M |
| 2 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.42M |
| 3 |
TXNM
TXNM Energy Inc
TXNM
|
+$3.29M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.26M |
| 5 |
Indivior Pharmaceuticals
INDV
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$4.25M |
| 2 |
Coupang
CPNG
|
+$4.1M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$3.46M |
| 4 |
TGNA
TEGNA Inc
TGNA
|
+$2.44M |
| 5 |
First Horizon
FHN
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.57% |
| 2 | Technology | 13.44% |
| 3 | Communication Services | 5.29% |
| 4 | Consumer Discretionary | 4.52% |
| 5 | Financials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Immuneering
IMRX
$296M
| $2.57M | 1.17% |
+253,110
| New | +$2.43M |
|
27
Cogent Biosciences
COGT
$7.06B
| $2.56M | 1.17% |
216,130
+32,146
| +17% | +$369K |
|
|
AMAM
28
DELISTED
Ambrx Biopharma Inc
AMAM
| $2.53M | 1.16% |
+153,431
| New | +$1.93M |
|
29
Legend Biotech
LEGN
$3.98B
| $2.51M | 1.15% |
36,385
+27,943
| +331% | +$1.83M |
|
30
Enliven Therapeutics
ELVN
$4.32B
| $2.47M | 1.13% |
+121,073
| New | +$2.45M |
|
|
BCYC
31
Bicycle Therapeutics
BCYC
$288M
| $2.36M | 1.08% |
92,434
| – | – |
|
|
XOMA
32
DELISTED
Xoma
XOMA
| $2.25M | 1.03% |
118,899
+25,524
| +27% | +$478K |
|
|
ACLX
33
DELISTED
Arcellx
ACLX
| $1.99M | 0.91% |
62,869
+8,589
| +16% | +$328K |
|
|
KRTX
34
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $1.97M | 0.9% |
+9,071
| New | +$1.94M |
|
35
Visa
V
$671B
| $1.93M | 0.88% |
8,127
+4,787
| +143% | +$1.1M |
|
|
RPTX
36
DELISTED
Repare Therapeutics
RPTX
| $1.75M | 0.8% |
165,173
+283
| +0.2% | +$2.92K |
|
37
Meta Platforms (Facebook)
META
$1.51T
| $1.69M | 0.77% |
+5,890
| New | +$1.45M |
|
38
Mastercard
MA
$491B
| $1.67M | 0.76% |
4,247
+2,577
| +154% | +$967K |
|
39
JD.com
JD
$45B
| $1.58M | 0.72% |
46,265
+38,085
| +466% | +$1.39M |
|
|
TERN
40
DELISTED
Terns Pharmaceuticals
TERN
| $1.57M | 0.72% |
179,670
+32,816
| +22% | +$382K |
|
41
PTC
PTC
$16.5B
| $1.38M | 0.63% |
9,681
+7,121
| +278% | +$943K |
|
42
Intuit
INTU
$91.1B
| $1.36M | 0.62% |
2,963
+1,743
| +143% | +$763K |
|
43
Amazon
AMZN
$2.99T
| $1.34M | 0.61% |
10,293
+3,723
| +57% | +$425K |
|
|
THRX
44
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $1.28M | 0.58% |
+136,719
| New | +$1.35M |
|
45
Bilibili
BILI
$7.91B
| $1.22M | 0.56% |
80,857
+65,867
| +439% | +$1.21M |
|
46
XPO
XPO
$23.6B
| $1.2M | 0.55% |
+20,280
| New | +$918K |
|
|
DICE
47
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $1M | 0.46% |
21,557
-45,800
| -68% | -$1.58M |
|
|
WWE
48
DELISTED
World Wrestling Entertainment
WWE
| $966K | 0.44% |
+8,907
| New | +$921K |
|
49
Booking.com
BKNG
$159B
| $964K | 0.44% |
8,925
+4,925
| +123% | +$520K |
|
50
Apollo Global Management
APO
$75.5B
| $958K | 0.44% |
+12,466
| New | +$834K |
|
Similar funds
SIAG
WI
MS
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2023 Portfolio in Review
As of Q2 2023, HighVista Strategies held 163 positions worth $219M, up 78% from $123M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
HighVista Strategies deployed $80.7M of net new capital in Q2 2023, opening 55 new positions and adding to 48 existing holdings. Its largest new stake was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 67% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.75M trimmed.
- HighVista Strategies's largest Q2 2023 buy was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
- HighVista Strategies added most to Invesco DB Commodity Index Tracking Fund in Q2 2023, an estimated $32.3M increase.
- HighVista Strategies's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $1.75M.
- HighVista Strategies fully exited iShares Russell 1000 Value ETF in Q2 2023, selling an estimated $4.25M.
- HighVista Strategies's ten largest holdings make up 34% of its $219M portfolio in Q2 2023.
- HighVista Strategies opened 55 new positions and closed 29 in Q2 2023.
- HighVista Strategies's portfolio value rose 78% quarter-over-quarter to $219M.
Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.